Equities

Acutus Medical Inc

AFIB:PKC

Acutus Medical Inc

Actions
  • Price (USD)0.0451
  • Today's Change0.003 / 6.18%
  • Shares traded88.48k
  • 1 Year change-94.81%
  • Beta0.0554
Data delayed at least 15 minutes, as of Jun 14 2024 20:49 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Acutus Medical, Inc. is focused on the production of left-heart access products under its distribution agreement with Medtronic, Inc. (Medtronic). The Company is solely focused on supporting the manufacturing and distribution of products to Medtronic. It manufactures transseptal crossing devices and associated accessories, such as integrated transseptal dilators and needles, fixed-curve or steerable introducers, and steerable sheaths (Products). These Products are used to access the left side, or left atrium, of the cardiac anatomy and are used in a range of medical applications, including in electrophysiology and structural heart procedures. The technology supports physicians during a critical component of an ablation or structural heart procedure. The transseptal crossing devices that it manufactures for Medtronic include versions that are length-, diameter- and tip-matched and designed to lock into the hub of sheaths used in many left-heart procedures.

  • Revenue in USD (TTM)9.55m
  • Net income in USD-9.70m
  • Incorporated2011
  • Employees233.00
  • Location
    Acutus Medical Inc2210 Faraday Ave Ste 100CARLSBAD 92008-7225United StatesUSA
  • Phone+1 (442) 232-6144
  • Fax+1 (858) 673-2274
  • Websitehttps://www.acutusmedical.com/us
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SETO Holdings Inc4.96m-652.00k1.02m18.00--0.0926--0.2057-0.056-0.0560.39940.1341.572.658.51---20.703.84-29.075.9552.8352.44-13.153.920.99211.240.3040.0019.015.44-61.23------
SPO Global Inc838.00k-540.00k1.10m2.00------1.31-85.99-85.99131.76-476.561.76-------113.56-305.39----31.1527.31-64.44-384.85---1.45-----17.09-15.1313.03------
Remedent Inc1.13m-259.38k1.10m16.00--0.2324--0.9743-0.013-0.0130.05650.23670.14743.452.69---3.247.35-5.2012.9365.3864.60-21.9721.200.2033-0.7720.00---33.63-21.70-140.31------
Invivo Therapeutics Holdings Corp0.00-9.33m1.24m6.00--0.1391-----3.53-3.530.002.870.00----0.00-81.32-73.69-94.35-85.63------------0.00-------6.01--19.74--
Escalon Medical Corp11.65m-296.71k1.26m38.00--1.22--0.1083-0.0401-0.04011.290.22592.403.757.51306,456.30-1.26-1.76-2.84-3.6744.0744.57-0.5265-0.91140.8927-1.620.1584--13.801.33760.89-17.06-19.85--
Grapefruit USA Inc34.85k-4.37m1.27m9.00------36.52-0.008-0.0080.00006-0.01010.01211.310.22593,872.22-151.85-268.93-----1,304.65-10.09-12,531.68-408.870.0388-1.50-----83.9677.87-35.68------
Acutus Medical Inc9.55m-9.70m1.34m233.00------0.1405-0.33010.09560.3261-0.13530.12111.141.4640,974.25-12.30-46.76-14.84-56.88-24.07-89.12-101.56-773.492.89-4.641.13--136.3627.03-141.35---35.99--
Nemaura Medical Inc0.00-10.65m1.41m36.00---------0.3787-0.37870.00-0.61690.000.00--0.00-117.49-58.18---131.96-------7,384.830.0305-1.4710.81---84.71---1.85--64.14--
Bone Biologics Corp0.00-6.10m1.66m2.00--0.4177-----23.10-23.100.003.620.00----0.00-114.93-98.31-189.37--------------0.00-------502.76------
Dynatronics Corp33.60m-5.14m1.91m154.00--0.256--0.0569-1.19-1.197.583.041.103.338.31218,173.30-14.35-6.02-19.94-8.3021.3727.33-13.07-4.550.6787-12.560.2188---8.41-8.81-19.84---5.11--
Kelyniam Global Inc517.70k-420.28k1.96m0.00--3.66--3.79-0.0253-0.02530.03120.01790.41357.044.38---33.57---41.79--18.86---81.18--1.26--0.6232---26.47---19.10------
Data as of Jun 14 2024. Currency figures normalised to Acutus Medical Inc's reporting currency: US Dollar USD

Institutional shareholders

2.04%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Apr 2024278.22k0.94%
Geode Capital Management LLCas of 30 Apr 2024185.00k0.62%
Two Sigma Securities LLCas of 31 Mar 202478.50k0.26%
Morgan Stanley & Co. LLCas of 31 Mar 202414.44k0.05%
HRT Financial LLCas of 31 Mar 202413.04k0.04%
Tower Research Capital LLCas of 31 Mar 202411.87k0.04%
Voisard Asset Management Groupas of 31 Mar 20248.70k0.03%
S.A. Mason LLCas of 31 Mar 20246.40k0.02%
AdvisorNet Financial, Inc.as of 31 Mar 20245.63k0.02%
Westside Investment Management LLCas of 31 Mar 20245.00k0.02%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.